AstraZeneca/Oxford vaccine 70% effective at tackling coronavirus

Grant Boone
November 23, 2020

"These findings show that we have an effective vaccine that will save many lives".

The vaccine's effectiveness depended on the dosing, and fell to just 62 percent when given as two full doses rather than a half-dose first.

The vaccine, developed with the University of Oxford, showed an average efficacy of 70% in preventing the coronavirus, according to the company. Speaking to the Today programme, Mr Hancock said: "If this all goes well in the next couple of weeks, then we are looking at the potential of starting the vaccination programme next month, for this Oxford/AstraZeneca vaccine as well as the Pfizer vaccine".

Another jab from Moderna, of which the United Kingdom has five million doses on order, is 95% effective, according to trial data.

One showed a vaccine efficacy of 90%.

The data means that lower doses could provide people a better protection from the novel coronavirus, SARS-COV2, which could effective lower the requirement of vaccine dosage per person.

AstraZeneca's announcement comes on the heels of two major announcements from USA companies, Pfizer and Moderna, about their progress in developing vaccines.

G20 to back 'equitable' access to coronavirus vaccine
Xi said in remarks in the backdrop of the over six-month-long military standoff between India and China in eastern Ladakh. But the group's leaders face mounting pressure to help stave off possible credit defaults across developing nations.

He added: "This is very welcome news, we can clearly see the end of tunnel now".

After the news release, AstraZeneca said it would prepare to send the data to regulators for conditional or early approval. He also said that further details on this development will be provided this evening.

Peter Doshi, an assistant professor of pharmaceutical health services at the University of Maryland and associate editor at the BBMJ, has argued that the phase-3 COVID-19 vaccine trials are not created to test for what we need to know - whether the vaccine candidate will prevent severe disease.

Over the weekend, Bharat Biotech in India had reported preliminary results from trials of its vaccine candidate as well - announcing an efficacy of 60%. That would make the AstraZeneca shot easier to transport and store globally, particularly in lower and middle-income countries.

AstraZeneca has become the latest drugmaker to unveil positive interim data in a race to curb the COVID-19 pandemic. The announcement of its efficacy follows news of successful vaccines from Pfizer and Moderna during November.

"That 90% is an intriguing result".

A week earlier, Pfizer Inc and Germany's BioNTech SE said their vaccine candidate had demonstrated greater than 90% efficacy, rising to 95% with analysis of full-trial data.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER